Trial Profile
Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 29 Aug 2017 New trial record